Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC versus NUMBRINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC versus NUMBRINO.
AMINOCAPROIC vs NUMBRINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Category C
Category C
Antifibrinolytic
Antifibrinolytic